Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Nasal Drug Delivery Technology Market, Dosage Form
7.1. Nasal Drug Delivery Technology Market, Dosage Form, 2021-2028
7.1.1. Spray
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Drops
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Gel
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Powder
7.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Nasal Drug Delivery Technology Market, Container Type
8.1. Nasal Drug Delivery Technology Market, Container Type, 2021-2028
8.1.1. Pressurized
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Non-pressurized
8.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Nasal Drug Delivery Technology Market, Therapeutic Application
9.1. Nasal Drug Delivery Technology Market, Therapeutic Application, 2021-2028
9.1.1. Nasal Congestion
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Rhinitis
9.1.2.1. Market Revenue and Forecast (2016-2028)
9.1.3. Asthma
9.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Nasal Drug Delivery Technology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.1.2. Market Revenue and Forecast, Container Type (2016-2028)
10.1.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.1.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.1.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.1.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.1.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.2.2. Market Revenue and Forecast, Container Type (2016-2028)
10.2.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.2.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.2.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.2.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.2.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.2.6.2. Market Revenue and Forecast, Container Type (2016-2028)
10.2.6.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.2.7.2. Market Revenue and Forecast, Container Type (2016-2028)
10.2.7.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.3.2. Market Revenue and Forecast, Container Type (2016-2028)
10.3.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.3.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.3.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.3.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.3.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.3.6.2. Market Revenue and Forecast, Container Type (2016-2028)
10.3.6.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.3.7.2. Market Revenue and Forecast, Container Type (2016-2028)
10.3.7.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.4.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.4.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.4.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.4.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.4.6.2. Market Revenue and Forecast, Container Type (2016-2028)
10.4.6.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.4.7.2. Market Revenue and Forecast, Container Type (2016-2028)
10.4.7.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.5.4.2. Market Revenue and Forecast, Container Type (2016-2028)
10.5.4.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, Dosage Form (2016-2028)
10.5.5.2. Market Revenue and Forecast, Container Type (2016-2028)
10.5.5.3. Market Revenue and Forecast, Therapeutic Application (2016-2028)
Chapter 11. Company Profiles
11.1. GlaxoSmithKline PLC
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca PLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Dickinson and Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Integra LifeSciences Corporation
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. OptiNose, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Becton
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Dickinson and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Promius Pharma, LLC
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Cadila Pharmaceuticals Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. B.F. Ascher & Company, Inc.
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. PendoPharm, Inc.
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Douglas Pharmaceuticals Ltd.
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. ENT Technologies Pty. Ltd.
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. NAVEH Pharma Ltd.
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms